Description
রেজিস্টার্ড চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন
Indications:
-
Treatment of chronic heart failure with reduced ejection fraction (HFrEF)
-
Reduces risk of cardiovascular death and hospitalization due to heart failure
-
Used to improve symptoms and quality of life in heart failure patients
Pharmacology:
Entresto combines:
-
Sacubitril: A neprilysin inhibitor that increases levels of natriuretic peptides, promoting vasodilation and sodium excretion.
-
Valsartan: An angiotensin II receptor blocker (ARB) that reduces vasoconstriction and lowers blood pressure.
The combination enhances heart function by reducing strain on the heart and preventing fluid retention.
Dosage & Administration:
-
Initial dose typically 50 mg twice daily, adjusted based on patient tolerance and renal function
-
Should be taken with or without food
-
Requires discontinuation of ACE inhibitors or ARBs 36 hours prior to starting Entresto
Interaction:
-
Avoid concurrent use with ACE inhibitors due to risk of angioedema
-
Caution with potassium-sparing diuretics or supplements to avoid hyperkalemia
-
Possible interactions with NSAIDs, lithium, and other antihypertensives
Contraindications:
-
History of angioedema related to ACE inhibitors or ARBs
-
Concomitant use with ACE inhibitors
-
Pregnancy and breastfeeding
-
Severe hepatic impairment
Side Effects:
-
Common: Hypotension, dizziness, hyperkalemia, cough
-
Less common: Renal impairment, angioedema, fatigue
-
Rare: Severe allergic reactions
Pregnancy & Lactation:
-
Pregnancy: Contraindicated due to fetal toxicity
-
Lactation: Not recommended
Precautions & Warnings:
-
Monitor blood pressure, kidney function, and electrolytes regularly
-
Educate patients to report signs of angioedema immediately
-
Use caution in patients with renal impairment or hypotension
Therapeutic Class:
Angiotensin receptor neprilysin inhibitor (ARNI)
Storage Conditions:
Store below 30°C in a dry, dark place. Keep out of reach of children.
Change Language